Zhejiang Xianju PharmaceuticalLtd Inkomsten in het verleden
Verleden criteriumcontroles 2/6
Zhejiang Xianju PharmaceuticalLtd has been growing earnings at an average annual rate of 9.1%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 2.4% per year. Zhejiang Xianju PharmaceuticalLtd's return on equity is 10.4%, and it has net margins of 15.1%.
Belangrijke informatie
9.1%
Groei van de winst
7.2%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 10.9% |
| Inkomstengroei | 2.4% |
| Rendement op eigen vermogen | 10.4% |
| Nettomarge | 15.1% |
| Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Zhejiang Xianju PharmaceuticalLtd (SZSE:002332) Seems To Use Debt Quite Sensibly
Oct 16
A Look At The Intrinsic Value Of Zhejiang Xianju Pharmaceutical Co.,Ltd. (SZSE:002332)
Sep 03Zhejiang Xianju PharmaceuticalLtd (SZSE:002332) Will Pay A Dividend Of CN¥0.30
Jun 02Estimating The Fair Value Of Zhejiang Xianju Pharmaceutical Co.,Ltd. (SZSE:002332)
Apr 15There Is A Reason Zhejiang Xianju Pharmaceutical Co.,Ltd.'s (SZSE:002332) Price Is Undemanding
Mar 05Opbrengsten en kosten
Hoe Zhejiang Xianju PharmaceuticalLtd geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 4,123 | 622 | 1,258 | 306 |
| 30 Jun 24 | 4,143 | 601 | 1,286 | 293 |
| 31 Mar 24 | 4,204 | 581 | 1,307 | 288 |
| 31 Dec 23 | 4,123 | 563 | 1,264 | 261 |
| 30 Sep 23 | 4,164 | 692 | 1,289 | 255 |
| 30 Jun 23 | 4,270 | 720 | 1,362 | 263 |
| 31 Mar 23 | 4,288 | 755 | 1,443 | 251 |
| 01 Jan 23 | 4,380 | 749 | 1,536 | 267 |
| 30 Sep 22 | 4,493 | 689 | 1,571 | 237 |
| 30 Jun 22 | 4,442 | 676 | 1,597 | 241 |
| 31 Mar 22 | 4,405 | 636 | 1,588 | 249 |
| 01 Jan 22 | 4,357 | 619 | 1,560 | 243 |
| 30 Sep 21 | 4,402 | 605 | 1,478 | 232 |
| 30 Jun 21 | 4,391 | 573 | 1,472 | 232 |
| 31 Mar 21 | 4,276 | 548 | 1,418 | 232 |
| 31 Dec 20 | 4,019 | 505 | 1,335 | 208 |
| 30 Sep 20 | 3,873 | 478 | 1,381 | 228 |
| 30 Jun 20 | 3,620 | 442 | 1,307 | 215 |
| 31 Mar 20 | 3,618 | 420 | 1,363 | 210 |
| 31 Dec 19 | 3,709 | 410 | 1,430 | 205 |
| 30 Sep 19 | 3,741 | 381 | 1,503 | 169 |
| 30 Jun 19 | 3,723 | 352 | 1,497 | 161 |
| 31 Mar 19 | 3,628 | 319 | 1,483 | 146 |
| 31 Dec 18 | 3,622 | 301 | 1,474 | 143 |
| 30 Sep 18 | 3,514 | 277 | 1,421 | 124 |
| 30 Jun 18 | 3,337 | 249 | 1,313 | 135 |
| 31 Mar 18 | 3,116 | 231 | 1,227 | 107 |
| 31 Dec 17 | 2,853 | 207 | 1,133 | 88 |
| 30 Sep 17 | 2,671 | 187 | 1,088 | 47 |
| 30 Jun 17 | 2,572 | 168 | 1,096 | 0 |
| 31 Mar 17 | 2,547 | 149 | 1,089 | 0 |
| 31 Dec 16 | 2,504 | 146 | 1,045 | 0 |
| 30 Sep 16 | 2,457 | 135 | 962 | 0 |
| 30 Jun 16 | 2,504 | 123 | 945 | 0 |
| 31 Mar 16 | 2,441 | 108 | 900 | 0 |
| 31 Dec 15 | 2,480 | 107 | 877 | 0 |
| 30 Sep 15 | 2,466 | 88 | 846 | 0 |
| 30 Jun 15 | 2,461 | 71 | 851 | 0 |
| 31 Mar 15 | 2,473 | 60 | 826 | 0 |
| 31 Dec 14 | 2,471 | 57 | 796 | 0 |
| 30 Sep 14 | 2,408 | 45 | 809 | 0 |
| 30 Jun 14 | 2,370 | 38 | 727 | 0 |
| 31 Mar 14 | 2,373 | 51 | 671 | 0 |
| 31 Dec 13 | 2,315 | 61 | 655 | 0 |
Kwaliteitswinsten: 002332 has high quality earnings.
Groeiende winstmarge: 002332's current net profit margins (15.1%) are lower than last year (16.6%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 002332's earnings have grown by 9.1% per year over the past 5 years.
Versnelling van de groei: 002332's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: 002332 had negative earnings growth (-10.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.2%).
Rendement op eigen vermogen
Hoge ROE: 002332's Return on Equity (10.4%) is considered low.